Inclusion Criteria:

- Male or female patients 18 years or older.

- Newly Diagnosed non-GCBsubtype of DLBCL (Stage II, III or IV).

- At least 1 measurable site of disease.

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Female subjects must be postmenopausal (for at least 6 months), surgically sterile,
abstinent, or, if sexually active, be practicing an effective method of birth control
before entry and throughout the study; and have a negative pregnancy test at
screening.

- Male subjects must agree to use a double barrier method of birth control

Exclusion Criteria:

- Prior treatment with VELCADE.

- Prior extended radiotherapy or chemotherapy for lymphoma

- More that 150 mg/m2 of prior doxorubicin

- Major surgery within 3 weeks of study.

- Peripheral neuropathy or neuralgia of Grade 2 or worse.

- Active CNS lymphoma

- Diagnosed or treated for a malignancy other than NHL, with some exceptions

- Pregnant or breast feeding

- Active systemic infection

- Documented of suspected human immunodeficiency virus (HIV)/AIDS

- Uncontrolled or severe cardiovascular disease

- Known allergies,hypersensitivity or intolerance to study drugs

- Serious medical condition that could interfere with study

- Concurrent treatment with another investigational agent